The content on this site is intended for healthcare professionals only
Dr Michel Ducreux talks to ecancer at ESMO 2012 in Vienna about emerging therapies for pancreatic cancer.
The prognosis for pancreatic cancer is often very poor with overall survival averaging 6 months with metastasis.
Dr Ducreux discuss on going trials that are testing the new compounds nab-paclitaxel and gemcitabine against the standard treatments. In addition the compund TH302, which fights against the cells even with hypoxia, was tested in comination with gemcitabine.
Filming supported by Amgen
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in head and neck cancer treatment in India
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Advancements in paediatric Acute lymphoblastic leukemia management
Enhancing head and neck oncology: Key insights from the conference
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Choosing 1st line TKI Wisely in patients with CML
